Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.69
- Piotroski Score 2.00
- Grade Overweight
- Symbol (SLS)
- Company SELLAS Life Sciences Group, Inc.
- Price $1.15
- Changes Percentage (4.11%)
- Change $0.05
- Day Low $1.08
- Day High $1.19
- Year High $1.72
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 12/09/2010
- Dividend Payable 12/20/2010
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $8.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.08
- Trailing P/E Ratio -1.34
- Forward P/E Ratio -1.34
- P/E Growth -1.34
- Net Income $-37,340,000
Income Statement
Quarterly
Annual
Latest News of SLS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers
SELLAS Life Sciences Group released positive preclinical data revealing ASXL1 mutation as a key predictor for SLS009 response in solid cancers. These findings validate the potential of ASXL1 mutations...
By Yahoo! Finance | 1 week ago -
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
Investing in unprofitable companies like Salesforce.com can yield significant returns, but cash burn rate is crucial. SELLAS Life Sciences Group had a cash runway of 8 months in September 2024, showin...
By Yahoo! Finance | 3 weeks ago -
Reshape Lifesciences Inc (RSLS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
Vyome Therapeutics targets malignant fungating wounds with its 1953 gel, addressing unmet medical needs. The company aims to create shareholder value by focusing on immuno-inflammation therapies. Thei...
By Yahoo! Finance | 3 weeks ago
